Medicine and Dentistry
Patient
100%
Neoplasm
39%
Therapeutic Procedure
31%
Overall Survival
26%
Pancreas Cancer
20%
Breast Cancer
16%
Survival
14%
Diagnosis
13%
Age
13%
Inpatient
12%
Malignant Neoplasm
10%
Surgery
10%
Tissues
9%
Lymph Node
9%
Progression Free Survival
9%
Programmed Death-Ligand 1
8%
Clinical Stage
8%
Neuroendocrine Tumor
7%
Assessment
7%
Merkel Cell Carcinoma
7%
Measurement
7%
Proportional Hazards Model
6%
Cancer
6%
Hepatocellular Carcinoma
6%
Gemcitabine
6%
Histopathology
6%
Neuroendocrine Carcinoma
5%
Diseases
5%
Upper Gastrointestinal Cancer
5%
Combination Therapy
5%
Chemotherapy
5%
Mitosis
5%
Immune Checkpoint Inhibitor
5%
Carcinoma
5%
Protein P53
5%
Adenocarcinoma
5%
Stereology
5%
Erlotinib
5%
Pharmacology, Toxicology and Pharmaceutical Science
Overall Survival
26%
Neoplasm
25%
Pancreas Cancer
20%
Survival
13%
Malignant Neoplasm
9%
Progression Free Survival
9%
Immune Checkpoint Inhibitor
7%
Breast Cancer
6%
Liver Cell Carcinoma
6%
Neuroendocrine Tumor
5%
Gemcitabine
5%
Neuroendocrine Carcinoma
5%
Protein P53
5%
Erlotinib
5%
Nursing and Health Professions
Patient
35%
Overall Survival
10%
Inpatient
9%
Neoplasm
7%
Chemotherapy
5%